personalized neoantigen vaccine NECVAX NEO1
Term · Oncology and biomedicine · MLC-T-ONC-015984
A personalized, oral Ty21a-based neoantigen vaccine consisting of eukaryotic expression plasmid encoding patient-specific tumor neoantigens that are immunogenic and unique to the patient's tumor, with potential immunomodulating and antineoplastic activities. Upon oral administration of personalized neoantigen vaccine NECVAX NEO1, the patient-specific neoantigens elicit a specific and potent cytotoxic T-lymphocyte (CTL) response against tumor cells expressing these neoantigens. Ty21a is a live-attenuated Salmonella typhi strain oral typhoid vaccine that is modified and used to deliver the neoantigens-encoding plasmids to the gut-associated lymphoid tissue.
| Identifier | MLC-T-ONC-015984 |
|---|---|
| Field | Oncology and biomedicine |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-015984",
"term": "personalized neoantigen vaccine NECVAX NEO1",
"field": "Oncology and biomedicine",
"definition": "A personalized, oral Ty21a-based neoantigen vaccine consisting of eukaryotic expression plasmid encoding patient-specific tumor neoantigens that are immunogenic and unique to the patient's tumor, with potential immunomodulating and antineoplastic activities. Upon oral administration of personalized neoantigen vaccine NECVAX NEO1, the patient-specific neoantigens elicit a specific and potent cytotoxic T-lymphocyte (CTL) response against tumor cells expressing these neoantigens. Ty21a is a live-attenuated Salmonella typhi strain oral typhoid vaccine that is modified and used to deliver the neoantigens-encoding plasmids to the gut-associated lymphoid tissue.",
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/personalized-neoantigen-vaccine-necvax-neo1/"
}
Record 13,024 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.